Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

.:: Noxxon Pharma (ALNOX) ::.

  • www.noxxon.com

Noxxon Pharma is a company specializing in cancer immunotherapy, listed on Euronext Growth Paris (ALNOX). Noxxon Pharma develops several products from its proprietary technology platform, including NOX-A12 and NOX-E36 that specifically address solid tumors such as colorectal cancer, pancreatic cancer and glioblastoma. 

The coverage was initiated Apr. 9th, 2018

Our target price for Noxxon Pharma as of Apr. 9th, 2018, is €17.95/ share

From Apr. 9th, 2018, Aurgalys analyst reports on Noxxon Pharma will be published in English and French

A partir du 9 avril 2018, les rapports d’analyse d’Aurgalys sur Noxxon Pharma seront publiés en Français et en Anglais